AtriCure

ATRC

Market cap $1.8B

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested.

AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.

The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

AtriCure, Inc. ( ATRC ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC John Young - Canaccord Genuity Corp., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Conway - Needham & Company, LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Third Quarter 2025 Earnings Conference Call.

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.